<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6414">
  <stage>Registered</stage>
  <submitdate>20/09/2016</submitdate>
  <approvaldate>20/09/2016</approvaldate>
  <nctid>NCT02910583</nctid>
  <trial_identification>
    <studytitle>Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma</studytitle>
    <scientifictitle>Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PCYC-1142-CA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia, Chronic Lymphocytic</healthcondition>
    <healthcondition>Lymphoma, Small Lymphocytic</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ibrutinib
Treatment: drugs - placebo to match ibrutinib
Treatment: drugs - venetoclax

Experimental: Pre-Randomization open-label ibrutinib + venetoclax - Subjects will receive 420mg capsules of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days)

Experimental: Ibrutinib (blinded) - Subjects that are MRD-negative will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity

Placebo Comparator: placebo to match ibrutinib - Subjects that are MRD-negative will be randomized to receive matching ibrutinib placebo capsules orally once daily on a continuous schedule until MRD-positive relapse, clinical disease progression or unacceptable toxicity

Experimental: Randomization open-label ibrutinib + venetoclax - Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules and venetoclax 400mg tablets orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity

Experimental: ibrutinib - Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous scheduled until clinical disease progression or unacceptable toxicity


Treatment: drugs: ibrutinib
ibrutinib 420mg capsules administered orally once daily

Treatment: drugs: placebo to match ibrutinib
placebo capsules to match ibrutinib administered orally once daily

Treatment: drugs: venetoclax
venetoclax tablets orally will be administered at 400mg once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>MRD-negative clinical response rate</outcome>
      <timepoint>approximately 40 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Disease free survival</outcome>
      <timepoint>approximately 52 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria (Hallek 2008), with active
             disease meeting at least 1 IWCLL criteria for requiring treatment.

          -  Measurable nodal disease by computed tomography (CT)

          -  Adequate hepatic, and renal function

          -  Adequate hematologic function

               -  absolute neutrophil count &gt;750/µL

               -  platelet count &gt;30,000 /µL

               -  hemoglobin &gt;8.0 g/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>69</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any prior therapy used for treatment of CLL/SLL

          -  Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk
             for TLS</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Site Reference ID/Investigator# 0654 - Kogarah</hospital>
    <hospital>Site Reference ID/Investigator # 0163 - Bedford Park</hospital>
    <hospital>Site Reference ID/Investigator # 0556 - Clayton</hospital>
    <hospital>Site Reference ID/Investigator# 0501 - Fitzroy</hospital>
    <hospital>Site Reference ID/Investigator #0715 - Frankston</hospital>
    <hospital>Site Reference ID/Investigator # 0170 - Heidelberg</hospital>
    <hospital>Site Reference ID/Investigator# 0633 - Melbourne</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Novara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piacenza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Aukland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmacyclics LLC.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Janssen Research &amp; Development, LLC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to determine the clinical minimum residual disease (MRD) response with the
      combination of ibrutinib plus venetoclax in subjects with treatment-naive chronic lymphocytic
      leukemia (CLL)/small lymphocytic lymphoma</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02910583</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joi Ninomoto, PharmD</name>
      <address>Pharmacyclics LLC.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>